Status:
TERMINATED
Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
University of Malaya
Conditions:
Occult Hepatitis B
Biological Substance; Adverse Effect
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to study the risk of hepatitis flare in patients with previous hepatitis B virus exposure amongst patients on immunosuppressive and biological modifier therapies
Detailed Description
Chronic hepatitis B infection remains a global health threat despite vaccination program.\[1\] Nearly 3 billion population are infected with chronic hepatitis B infection globally. In China, the poole...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old at the time of starting biological modifier therapies or at the time of recruitment
- Positive for anti-HBc OR
- Positive for anti-HBs and born before year 1988
Exclusion
- Known HBV carrier with HBsAg positive
- Concomitant HCV and/ or HIV infection
- Already on HBV anti-viral
- Refuse to consent
- Baseline ALT \> 80 IU/ml
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 12 2022
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04356404
Start Date
May 1 2020
End Date
January 12 2022
Last Update
January 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong